1 active not recruiting, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Refractory Acute Biphenotypic Leukemia: new trials by email Literature Review of Refractory Acute Biphenotypic Leukemia trials Research Report on Refractory Acute Biphenotypic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 Omacetaxine Mepesuccinate, Venetoclax - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Biphenotypic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 24 | 2021-12-17 | 2025-11-03 |
| Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Decitabine and Cedazuridine, Venetoclax - Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 20 | 2021-09-29 | 2026-11-12 |
Leukemia, Biphenotypic, Acute (2) · Leukemia, Myeloid, Acute (2) · Hematologic Neoplasms (1) · Myelodysplastic Syndromes (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia (2) · Leukemia, Lymphoid (2) · Leukemia, Myeloid (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Bone Marrow Diseases (1) · Neoplasms by Site (1)
venetoclax (2) · Esters (1) · Homoharringtonine (1) · decitabine and cedazuridine drug combination (1)
M.D. Anderson Cancer Center (2)
United States (2)
Abhishek Maiti (1) · Courtney DiNardo, MD (1)